VCI Wealth Management LLC Purchases 406 Shares of Danaher Co. (NYSE:DHR)

VCI Wealth Management LLC lifted its position in Danaher Co. (NYSE:DHR) by 5.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,422 shares of the conglomerate’s stock after buying an additional 406 shares during the quarter. VCI Wealth Management LLC’s holdings in Danaher were worth $1,933,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. FMR LLC grew its stake in shares of Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after buying an additional 3,217,631 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Danaher by 3.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock valued at $1,417,342,000 after purchasing an additional 148,251 shares during the last quarter. Fisher Asset Management LLC lifted its holdings in Danaher by 2.6% during the 3rd quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock valued at $1,265,725,000 after purchasing an additional 116,299 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in Danaher by 17.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after purchasing an additional 535,254 shares during the last quarter. Finally, Montrusco Bolton Investments Inc. lifted its holdings in Danaher by 30.4% during the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock valued at $465,617,000 after purchasing an additional 397,671 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Danaher Stock Performance

NYSE:DHR opened at $250.51 on Tuesday. The stock has a market cap of $180.94 billion, a P/E ratio of 47.81, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The stock’s 50-day moving average is $235.33 and its 200-day moving average is $253.62. Danaher Co. has a 1-year low of $225.42 and a 1-year high of $281.70.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.43%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio is currently 20.61%.

Analysts Set New Price Targets

Several brokerages have issued reports on DHR. Royal Bank of Canada cut their price target on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Barclays cut their price target on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Robert W. Baird dropped their target price on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. KeyCorp lifted their target price on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Finally, Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price for the company in a report on Friday, December 13th. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $285.55.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.